STipe Therapeutics ApS (under frivillig likvidation)Aktiv
Økonomiske nøgletal
Nøgletal
2024Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Koncernregnskab
2019- Bruttofortjeneste
- -9.928.245 kr.
- Resultat af primær drift
- -15.447.489 kr.
- Årets resultat
- -13.306.163 kr.
- Egenkapital
- 49.902.775 kr.
- Aktiver i alt
- 60.039.706 kr.
- Ansatte
- 7
Tallene ovenfor på siden gælder selskabet alene (modervirksomheden); koncerntallene omfatter også dattervirksomheder.
Regnskabstal2019–2024
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Balance — aktiver | ||||||
| Likvide beholdninger | 56.710.167 | 26.452.750 | 41.906.125 | 39.680.441 | 17.226.498 | 8.382.489 |
| Omsætningsaktiver i alt | 60.039.706 | 34.502.015 | 108.255.641 | 46.265.667 | 24.003.386 | 8.382.489 |
| Anlægsaktiver i alt | — | — | — | — | — | — |
| Aktiver i alt | 60.039.706 | 34.502.015 | 108.255.641 | 46.265.667 | 24.003.386 | 8.382.489 |
| Balance — passiver | ||||||
| Kortfristede gældsforpligtelser | 2.938.516 | 5.596.171 | 11.346.332 | 9.970.670 | 4.211.953 | 269.649 |
| Langfristede gældsforpligtelser | 7.198.423 | 823.330 | 20.579.425 | 21.680.058 | 38.419.231 | 0 |
| Gældsforpligtelser i alt | 10.136.939 | 6.419.502 | 31.925.756 | 31.650.729 | 42.631.185 | 269.649 |
| Selskabskapital | 128.215 | 128.215 | 239.183 | 239.183 | 239.183 | 258.974 |
| Overført resultat | 49.774.552 | 27.954.299 | 16.625.677 | 14.375.756 | -18.866.982 | 7.853.866 |
| Årets resultat | -13.306.163 | -28.852.684 | -40.921.024 | -61.714.946 | -33.242.730 | 10.807.660 |
| Egenkapital i alt | 49.902.767 | 28.082.514 | 76.329.884 | 14.614.938 | -18.627.799 | 8.112.840 |
| Resultatopgørelse | ||||||
| Bruttofortjeneste | -9.928.245 | -21.997.466 | -30.485.887 | -49.144.272 | -25.785.915 | -6.283.446 |
| Resultat af primær drift | -15.447.489 | -33.994.310 | -45.335.987 | -65.713.887 | -36.983.465 | -11.188.239 |
| Resultat før skat | -16.060.552 | -34.345.370 | -46.413.710 | -67.207.632 | -38.735.416 | 10.807.660 |
| Årets resultat | -13.306.163 | -28.852.684 | -40.921.024 | -61.714.946 | -33.242.730 | 10.807.660 |
| Personaleomkostninger | 5.519.244 | 11.996.844 | 14.850.100 | 16.569.615 | 11.197.550 | 4.904.793 |
| Af- og nedskrivninger | — | — | — | — | — | — |
| Andre nøgletal | ||||||
| Ansatte | 7 | 14 | 16 | 16 | 14 | 5 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2024The company's key activity is to develop novel treatments that focuses on harnessing the innate immune system to battle cancer.
The income statement for 2024 shows a profit of EUR 1,449 thousand against a loss of EUR 4,456 thousand last year, and the balance sheet at 31 December 2024 shows equity of EUR 1,088 thousand. The loss for the year is according to expectations. Stipe Therapeutics ApS has entered voluntary liquidation in the financial year 2024. Lawyer Preben Jakobsen was appointed as the liquidator in connection with the registration of the voluntary liquidation. In this regard, a solvent liquidation plan has been prepared, and a remission of debt has been received from both the legal owners and third parties. The remission of debt has resulted in a financial income of EUR 3,225 thousand which has been recognized under the accounting item "Financial income" and similarly reduced the long-term debt ''Credit Institution'' and Convertible loan'' obligations with EUR 3,225 thousand. Reference is made to note 2 for more details.
Uddrag af ledelsesberetningen i den seneste årsrapport.